骨癌治療市場規模- 按類型（原發性、[骨肉瘤、軟骨肉瘤]、繼發性）、治療（標靶和免疫治療[狄諾塞麥、伊馬替尼]、化療[阿黴素、順鉑]）、治療提供者和預測，2024 - 2032 年

Bone Cancer Treatment Market Size - By Type (Primary, [Osteosarcoma, Chondrosarcoma], Secondary), Treatment (Targeted and Immunotherapy [Denosumab, Imatinib], Chemotherapy [Doxorubicin, Cisplatin]), Treatment Provider & Forecast, 2024 - 2032

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 226 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球骨癌治療市場在 2024 年至 2032 年間將經歷 5% 的複合年成長率，更好的診斷技術將透過實現準確檢測徹底改變骨癌管理。根據美國癌症協會 (ACS) 的報告，過去十年先進影像技術的使用增加了約 15%，有助於早期診斷的增加和治療結果的改善。

診斷創新促進了精確的腫瘤定位和基因分析，有助於根據個別患者的需求量身定做治療計劃。早期發現可以提高治療效果並提高存活率。此外，患者對個人化治療的偏好的轉變以及醫療保健提供者的積極主動的方法將增強未來幾年的行業動態。

整個骨癌治療市場根據類型、治療、治療提供者和地區進行分類。

由於原發性癌症轉移的普遍存在，到 2032 年，次要部分將出現顯著的複合年成長率。由於初始治療的創新，原發性癌症（例如乳腺癌或前列腺癌）患者的壽命更長，繼發性骨癌是一個重大問題。這種轉變導致對骨轉移的專門治療的需求更高。醫學影像和監測的改進加強了繼發性骨癌的檢測，從而實現早期干預。這些因素導致對繼發性骨癌治療的需求不斷成長。

由於新型化療藥物的療效和可用性不斷提高，到 2032 年，化療領域將佔據顯著的骨癌治療市場。這些藥物在治療局部骨癌和轉移性骨癌方面顯示出改善的結果，為患者提供了更有效的治療選擇。眾所周知，化療可以縮小腫瘤大小並控制疾病進展。此外，聯合療法和個人化化療方案的進步正在提高治療效果，促進細分市場的成長。

由於人口老化和骨癌盛行率增加，2024年至2032年歐洲骨癌治療市場將錄得令人印象深刻的複合年成長率。該地區擁有增強的醫療基礎設施和先進的治療選擇。對尖端研究的大量投資以及對提供全面護理的關注正在改善患者的治療效果。此外，意識的提高和早期檢測計劃正在導致更高的診斷率，從而推動了對有效治療解決方案的需求。隨著醫療保健系統的發展和資源的擴大，歐洲對先進骨癌治療的需求將繼續呈上升趨勢。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Advaxis Inc.
Amgen Inc.
Atlanthera
Baxter International Inc.
Bayer AG
Debiopharm
Eli Lilly and Company
Gradalis Inc.
Hikma Pharmaceutical PLC
Johnson & Johnson
Novartis AG
Pfizer Inc.
Recordati Group
Spectrum Pharmaceuticals Inc.
Takeda Pharmaceutical Company

簡介目錄

Product Code: 9585

Global Bone Cancer Treatment Market will experience a 5% CAGR between 2024 and 2032, ascended by better diagnostic techniques that revolutionize bone cancer management by enabling accurate detection. According to the American Cancer Society (ACS) reports, the use of advanced imaging techniques has increased by about 15% over the past decade, contributing to a rise in early-stage diagnoses and improved management outcomes.

The diagnostic innovations facilitate precise tumor localization and genetic profiling, which help in tailoring treatment plans to individual patient needs. Early detection boosts treatment outcomes as well as enhances survival rates. Further, the shifting preference for personalized treatment among patients and proactive approach by healthcare providers will augment the industry dynamics in the coming years.

The overall bone cancer treatment market is classified based on type, treatment, treatment provider, and region.

The secondary segment will register a remarkable CAGR through 2032, due to the prevalence of metastasis from primary cancers. As patients with primary cancers, such as breast or prostate cancer, live longer due to innovations in initial treatments, secondary bone cancer is a significant concern. This shift results in a higher need for specialized treatments targeting bone metastases. Improvements in medical imaging and monitoring have strengthened the detection of secondary bone cancers, leading to earlier intervention. These factors contribute to the thriving demand for secondary bone cancer treatments.

The chemotherapy segment will clutch a notable bone cancer treatment market share by 2032, because of the increasing efficacy and availability of novel chemotherapy agents. These agents are showing improved outcomes in managing both localized and metastatic bone cancer, providing patients with more effective treatment options. Chemotherapy is known to reduce tumor size and control disease progression. Additionally, advancements in combination therapies and personalized chemotherapy regimens are enhancing treatment efficacy, escalating segment growth.

Europe bone cancer treatment market will record an impressive CAGR from 2024 to 2032, owing to an aging population and increased prevalence of bone cancer. The region boasts enhanced healthcare infrastructure and advancements in treatment options. The inflowing investment in cutting-edge research and focus on offering comprehensive care are resulting in improved patient outcomes. Additionally, increased awareness and early detection programs are leading to higher diagnosis rates, fueling the need for effective treatment solutions. As healthcare systems evolve and resources expand, the demand for advanced bone cancer treatments will continue its upward trajectory in Europe.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of bone cancer
  - 3.2.1.2 Growing awareness and early diagnosis
  - 3.2.1.3 Advancements in medical technology and treatment modalities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High treatment costs
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Primary bone cancer
- 5.2.1 Osteosarcoma
- 5.2.2 Chondrosarcoma
- 5.2.3 Ewing sarcoma
- 5.2.4 Other primary bone cancer
5.3 Secondary bone cancer

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Targeted and immunotherapy
- 6.2.1 Denosumab
- 6.2.2 Imatinib
- 6.2.3 Sunitinib
- 6.2.4 Other targeted & immunotherapies
6.3 Chemotherapy
- 6.3.1 Doxorubicin
- 6.3.2 Cisplatin
- 6.3.3 Etoposide
- 6.3.4 Cyclophosphamide
- 6.3.5 Other chemotherapies
6.4 Radiation therapy
6.5 Surgery

Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Oncology centers & specialty clinics
7.4 Ambulatory surgical centers (ASCs)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa